The escalating trade war between Washington and Beijing dominated discussions at the G-7 gathering in France.Politicsread more
Neither the U.S. nor China wants to be seen as the party that derailed trade talks, says William Reinsch of Center for Strategic and International Studies.World Economyread more
Megvii is known for its facial recognition technology and while revenue grew over 350% in 2018, its losses have widened.Technologyread more
PARIS, Aug 6 (Reuters) - The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.
The European Commission has extended the marketing authorisation for Dupixent in the European Union to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, Sanofi and Regeneron said in a joint statement.
Dupixent is now the first biologic medicine approved in the EU to treat these patients, according to the companies.
Last month, Sanofi reported a surge in Dupixent's sales as the company posted strong second-quarter results. (Reporting by Sudip Kar-Gupta; editing by Gopakumar Warrier)